Protein tyrosine phosphatase mutations in cancers
Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis. A mutational analysis of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14), affecting 26% of colorectal cancers and a smaller fraction of lung, breast and gastric cancers. Fifteen mutations were nonsense, frameshift or splice site alterations predicted to result in truncated proteins lacking phosphatase activity. Five missense mutations in the most commonly altered PTP (PTPRT) were biochemically examined and found to reduce phosphatase activity. Expression of wild-type but not a mutant PTPRT in human cancer cells inhibited cell growth. These observations suggest that the tyrosine phosphatase genes are tumor suppressor genes, regulating cellular pathways that may be amenable to therapeutic intervention.
1. A method of categorizing human cancers selected from the group consisting of lung, colorectal, and gastric cancer tissues, comprising:
determining the coding sequence for protein tyrosine phosphatase family member PTPRT in a sample of a cancer tissue selected from the group consisting of lung, colorectal, and gastric cancer tissues;
identifying a somatic mutation of said protein tyrosine phosphatase family member in the cancer tissue;
assigning the cancer tissue to a group based on the presence or absence of the somatic mutation.
2. The method of claim 1 wherein the mutation is one which truncates the protein tyrosine phosphatase family member.
3. The method of claim 1 wherein the mutation is non-synonymous.
4. The method of claim 1 wherein the mutation is a point mutation.
5. The method of claim 1 wherein the group is used to identify cancer.
6. The method of claim 1 wherein the cancer tissue is colorectal.
7. The method of claim 1 wherein the cancer tissue is lung.
8. The method of claim 1 wherein the cancer tissue is gastric.
9. A method of testing a sample collected from a human, comprising:
determining the coding sequence for protein tyrosine phosphatase family member PTPRT in the sample collected from the human, wherein the sample is selected from the group consisting of:
a suspected colorectal cancer tissue,
a suspected gastric cancer tissue,
a suspected lung cancer tissue, and
blood, serum, plasma, or stool of a human who has a colorectal, gastric, or lung cancer;
identifying a somatic mutation of said protein tyrosine phosphatase family members in the sample, wherein the somatic mutation diminishes the expression and/or enzymatic function of PTPRT.
10. The method of claim 9 wherein the sample is selected from the group consisting of a suspected colorectal cancer tissue, a suspected gastric cancer tissue, a suspected lung cancer tissue, blood, and stool.
11. The method of claim 1 wherein the somatic mutation diminishes the expression and/or enzymatic function of PTPRT.
12. The method of claim 1 wherein the step of determining the coding sequence is performed using primers.
13. The method of claim 9 wherein the step of determining the coding sequence is performed using primers.
14. The method of claim 1 wherein the step of determining the coding sequence employs DNA amplification.
15. The method of claim 9 wherein the step of determining the coding sequence employs DNA amplification.
16. The method of claim 1 wherein the step of determining the coding sequence employs dye terminators.
17. The method of claim 9 wherein the step of determining the coding sequence employs dye terminators.
18. The method of claim 1 wherein the step of determining the coding sequence is performed on genomic DNA.
19. The method of claim 9 wherein the step of determining the coding sequence is performed on genomic DNA.
20. The method of claim 1 wherein the step of determining the coding sequence is performed on amplified exons.
21. The method of claim 9 wherein the step of determining the coding sequence is performed on amplified exons.